About ViaCord
ViaCord is a company based in Hebron (United States) founded in 1993 by Cynthia Fisher was acquired by PerkinElmer in October 2007. ViaCord has raised $84.5 million across 3 funding rounds from investors including Amgen, PerkinElmer and Nomura. ViaCord offers products and services including Cord Blood Banking, Cord Tissue Banking, Genetic Insight Panel, and Whole Genome Sequencing. ViaCord operates in a competitive market with competitors including BridgeBio, Spark Therapeutics, Alnylam, ATAI and Insitro, among others.
- Headquarter Hebron, United States
- Founders Cynthia Fisher
-
Sectors
Healthcare
-
Email
Locked
-
Phone
Locked
-
Website
Locked
-
Social
Locked
-
Annual Revenue
Not available
-
Net Profit
Not available
-
EBITDA
Not available
-
Total Equity Funding
$84.5 M (USD)
in 3 rounds
-
Latest Funding Round
$20 M (USD), Series C
Dec 31, 2003
-
Investors
Amgen
& 8 more
-
Employee Count
Not available
-
Acquired by
PerkinElmer
(Oct 02, 2007)
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Products & Services of ViaCord
ViaCord offers a comprehensive portfolio of products and services, including Cord Blood Banking, Cord Tissue Banking, Genetic Insight Panel, and Whole Genome Sequencing.
Service to collect and store umbilical cord blood stem cells.
Preserves cord tissue for potential regenerative treatments.
Analyzes genes for actionable health conditions in newborns.
Sequences genes to identify health risks and drug sensitivities.
Funding Insights of ViaCord
ViaCord has successfully raised a total of $84.5M across 3 strategic funding rounds. The most recent funding activity was a Series C round of $20 million completed in December 2003. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.
Investors in ViaCord
ViaCord has secured backing from 9 investors, including institutional and venture fund investors. Prominent investors backing the company include Amgen, PerkinElmer and Nomura.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
|
Private equity firm focused on multiple sectors
|
Locked | Locked | Locked | |
|
-
|
Locked | Locked | Locked | |
|
Healthcare investments are made by Tullis Health Investors.
|
Locked | Locked | Locked |
Investor details for ViaCord
Investor domains, locations, round participation, and complete history require an active premium plan.
- Investor domains
- Investor locations
- Funding rounds
- Participation history
Verified entity values are shown only after access is granted.
Investments & Acquisitions by ViaCord
Investment portfolio details for ViaCord
Portfolio company identities, transaction dates, round details, and investment values require an active premium plan.
- Portfolio identities
- Transaction dates
- Round details
- Investment values
Verified entity values are shown only after access is granted.
Financial Statements - ViaCord
Detailed financials for ViaCord
Historical revenue, profit, statement rows, ratios, and trend charts require an active premium plan.
- Historical revenue
- Profit trends
- Statement rows
- Financial ratios
Verified entity values are shown only after access is granted.
Viacord Comparisons
Peer comparison for ViaCord
Named peer metrics, headcount, funding, location, and side-by-side benchmarks require an active premium plan.
- Named peers
- Headcount comparison
- Funding comparison
- Operating benchmarks
Verified entity values are shown only after access is granted.
Competitors of ViaCord
ViaCord operates in a dynamic and competitive business environment, facing competition from various established players and emerging companies in the market. The competitive landscape includes prominent companies such as BridgeBio, Spark Therapeutics, Alnylam, ATAI and Insitro, among others.
| Company Name | Domain | Founded year | HQ Location | Description |
|---|---|---|---|---|
| Locked | Locked | Locked |
Therapeutics for genetic diseases are developed through targeted interventions.
|
|
| Locked | Locked | Locked |
Gene therapies for rare diseases including retinal dystrophies are developed.
|
|
| Locked | Locked | Locked |
RNA interference-based therapeutics are developed for multiple disorders.
|
|
| Locked | Locked | Locked |
A biopharmaceutical company accelerating innovative mental health treatments.
|
|
| Locked | Locked | Locked |
An AI-enabled platform is developed for infectious disease treatment.
|
|
| Locked | Locked | Locked |
Cordlife is engaged in cord blood banking and diagnostics.
|
Detailed competitors of ViaCord
Competitor domains, locations, full profiles, and operating metrics require an active premium plan.
- Domains and locations
- Full company profiles
- Operating metrics
- Competitive positioning
Verified entity values are shown only after access is granted.
Latest news on Viacord
Complete news archive for ViaCord
Full article history, source details, and older brand coverage require an active premium plan.
- Full article archive
- Source and publication date
- Older coverage
- Brand-specific news history
Verified entity values are shown only after access is granted.
Frequently Asked Questions about ViaCord
ViaCord was founded in 1993 and raised its 1st funding round 7 years after it was founded.
ViaCord is headquartered in Hebron, United States. It is registered at Hebron, Connecticut, United States.
ViaCord is a funded company, having raised a total of $84.5M across 3 funding rounds to date.
ViaCord was founded in 1993 in Hebron, United States, within the healthcare and biotechnology sectors. Cord blood from newborns umbilical cords is collected and stored by the company for potential future treatments of conditions like leukemias, immune deficiencies, and metabolic disorders. Genetic testing services are also made available to support therapeutic choices. Operations center on family preservation programs across the United States.
ViaCord's top competitors include Spark Therapeutics, BridgeBio and Forge Biologics.
ViaCord offers Cord Blood Banking, Cord Tissue Banking, Genetic Insight Panel, and Whole Genome Sequencing.
ViaCord has 9 investors. Key investors include Amgen, PerkinElmer, Nomura, Genzyme, and Singapore Economic Development Board.